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Abstract
Aberrant overexpression of cyclooxygenase-2 (COX2) is observed in urothelial carcinoma of the bladder (UCB). Studies
evaluating COX2 as a prognostic marker in UCB report contradictory results. We determined the prognostic potential of
COX2 expression in UCB and quantitatively summarize the results with those of the literature through a meta-analysis.
Newly diagnosed UCB patients recruited between 1998–2001 in 18 Spanish hospitals were prospectively included in the
study and followed-up (median, 70.7 months). Diagnostic slides were reviewed and uniformly classified by expert
pathologists. Clinical data was retrieved from hospital charts. Tissue microarrays containing non-muscle invasive (n = 557)
and muscle invasive (n = 216) tumours were analyzed by immunohistochemistry using quantitative image analysis.
Expression was evaluated in Cox regression models to assess the risk of recurrence, progression and disease-specific
mortality. Meta-hazard ratios were estimated using our results and those from 11 additional evaluable studies. COX2
expression was observed in 38% (211/557) of non-muscle invasive and 63% (137/216) of muscle invasive tumors. Expression
was associated with advanced pathological stage and grade (p,0.0001). In the univariable analyses, COX2 expression - as a
categorical variable - was not associated with any of the outcomes analyzed. As a continuous variable, a weak association
with recurrence in non-muscle invasive tumors was observed (p-value = 0.048). In the multivariable analyses, COX2
expression did not independently predict any of the considered outcomes. The meta-analysis confirmed these results. We
did not find evidence that COX2 expression is an independent prognostic marker of recurrence, progression or survival in
patients with UCB.
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Introduction
Urothelial carcinoma of the bladder (UCB) is the most common
bladder cancer type in developed nations [1]. UCB predominantly
manifests (70–80% of patients) as a non-muscle invasive tumor
(NMIBC: pTa-pT1) characterized by an overall good prognosis
following transurethral resection in patients with low-grade tumors
(pTaG1/2), and intravesical chemotherapy and/or Bacillus
Calmette Guerin (BCG) instillation in patients with high-grade
tumors (pTaG3 or pT1G2/3) [2]. Approximately 70% of NMIBC
patients suffer a recurrence following treatment and a further 15%
progress, developing new tumors exhibiting muscle invasion
(MIBC: pT2-pT4); the risk of progression being higher among
patients with high-grade tumors [2]. Due to a high rate of
recurrence and the need for close follow-up over a patient’s
lifetime, UCB remains one of the most expensive tumors to treat
on a per patient basis [3]. A lower proportion (20–30%) of UCB
patients are diagnosed with muscle invasive tumors (MIBC; pT2-
pT4) characterized by poor prognosis: 50% of these patients die
from their cancer [2]. Genomic profiling and gene expression
analyses indicate a strong correlation between these pathologic
classifications and the underlying molecular architecture of UCB
[4].
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Growing evidence indicates that chronic inflammation may
increase the risk of UCB [5]. Studies investigating the prolonged
use of cyclooxygenase-2 (COX2) inhibiting non-steroidal anti-
inflammatory drugs (NSAIDs) have reported a decrease in UCB
risk [6,7]. COX2 is a prostaglandin endoperoxide synthetase that
catalyzes the production of prostanoids upon induction by
proinflammatory cytokines, growth factors, tumor promoters and
other external stimuli [8]. COX2 activation mediates cellular
processes also implicated in carcinogenesis such as angiogenesis,
cell survival/proliferation and apoptosis [9]. Moreover, studies
have shown that bladder tissue from patients with cystitis or UCB
exhibits elevated COX2 levels in contrast to benign bladder tissue
[10,11].
While numerous groups have investigated the prognostic
potential of COX2 expression in UCB [12–31], there is no clear
consensus on its utility. The objective of this study was to assess
whether COX2 protein expression in UCB cells is associated with
prognosis using a large and standardized cohort of newly
diagnosed bladder cancer patients. A meta-analysis was also done
to summarize these results together with those from other studies
published on the topic.
Materials and Methods
Study Population
A total of 773 newly diagnosed UCB cases aged 22–80 years
(mean 6 SD = 66610 yrs) with a median follow-up of 70.7
months (range 0.7–117.7 months) and available tumor tissue were
used in the current analysis. All cases were recruited between 1998
and 2001 from 18 hospitals in five regions of Spain as part of the
Spanish Bladder Cancer (SBC)/EPIdemiology of Cancer of the
UROthelium (EPICURO) study, a hospital-based case-control
study described previously [32]. A pathologist review panel
uniformly classified the T stage and grade (G) of each tumor
biopsy according to the criteria of the TNM classification and the
WHO-ISUP [33], using the three grade redefinition provided by
the WHO [34,35]. All bladder tumor samples used in the study
were collected prior to the administration of any intravesical or
systemic therapy. Clinical information related to diagnostic
procedures, tumor characteristics and treatment was collected
from medical records, and a computerized questionnaire was used
for the collection of sociodemographic data. NMIBCs were
removed by transurethral resection and patients received intra-
vesical chemo- or immunotherapy (i.e. BCG) as appropriate. The
majority of patients presenting with MIBCs were treated by
radical cystectomy; in cases where surgery was not possible,
radiotherapy or systemic chemotherapy were administered.
Follow-up information was collected annually from hospital
records and through direct telephone interviews by trained
monitors using structured questionnaires. Among NMIBCs,
recurrence was defined as the appearance of a new NMIBC
following a previous negative follow-up cystoscopy, and progres-
sion, as the development of a MIBC. In patients initially
presenting with MIBCs, any tumor reappearance after treatment
was considered progression, regardless of whether the tumor
relapse was local or distal. Tumour-specific survival was assessed
only for patients with MIBCs. Informed written consent was
obtained from study participants in accordance with the Ethics
Committees of each participating hospital.
Immunohistochemistry
Tissue blocks of formalin-fixed, paraffin-embedded primary
bladder tumors were used to construct tissue microarrays (TMA)
containing tumor cores of 0.6-mm in diameter represented in
duplicate and selected from the most representative regions of the
tumor on which T and G were based. After deparaffinisation and
heat-induced antigen retrieval, all slides were stained simulta-
neously at the Histology and Immunohistochemistry Core Unit of
the CNIO using the PT LINK system as per manufacturer’s
instructions (Dako Inc., Glostrup, Denmark). Briefly, tissue
sections were incubated with anti-COX2 rabbit monoclonal
antibody (ThermoFisher Scientific, Fremont, CA, USA; #RM-
9121-R7; pre-diluted, ready-to-use) at room temperature, followed
by visualization using the EnVision Flex Visualization system
(Dako Inc., Glostrup, Denmark) and exposure to diaminobenze-
dine. Tissues were then counterstained with haematoxylin,
dehydrated and mounted. A section of colon tissue was used as
a positive control.
Evaluation of COX2 Immunostaining
COX2 expression was quantified using the Ariol SL-50 (version
3.1.2, Applied Imaging Corp., San Jose, CA, USA) high-
throughput slide imaging scanner. All cores were imaged and
processed using a light microscope and the accompanying TMA
Multistain Imaging software. The program was trained by a
pathologist (SM) to maximize the inclusion of positively stained
tumor epithelium while minimizing stromal material, as described
previously [36]. COX2 expression score was calculated as the
product of the mean intensity of staining (by defining the
background and saturation limits of the antibody and imaging
sensor, respectively) and the proportion of cellular antibody-
positive area divided by total cellular area. Values from replicate
cores were averaged to provide a final expression score for each
patient. Furthermore, one randomly selected TMA (representing
10% of all cores) was analyzed by direct visual microscopic
inspection by an independent pathologist (MMM) to enable
comparison with the automated scoring approach. The patholo-
gist-derived score was calculated as the product of COX2 staining
intensity (1 = weak, 2 = intermediate, 3 = strong) and a quartile of
the percentage of epithelial tumor cells stained (0–4; with 0
representing 0% staining), providing a final categorical score in the
range of 0–12. There was a high and significant correlation
between the machine and pathologist derived scores (Spearman
rho = 0.85; 95%CI = 0.79–0.90; p-value,0.00001). COX2 ex-
pression was analyzed as both a continuous variable and
categorical variables partitioned at the median and extreme
tertiles. Additionally, expression was examined as a categorical
variable dichotomized at a threshold (0.340 arbitrary units [au])
above which COX2 expression was considered to be positive. This
expression threshold was derived by comparing the pathologist’s
(MMM) binary assignment of positive expression (i.e. score of 0 vs.
score $1, as described above) to the machine-derived continuous
score using receiver operating characteristic (ROC) curve analysis
(area under the curve = 0.95; 86% sensitivity and 92% specificity)
[37].
Meta-analysis
The meta-analysis included COX2 expression results from our
own series (using the ROC-derived categorical expression variable)
and relevant studies published before 1 January 2012 identified by
searching PubMed and ISI Web of Knowledge. The search string
used was: (cox2 OR cox-2 OR cyclooxygenase-2 OR "cycloox-
ygenase 2" OR ptgs2) AND (prognos* OR survival OR mortality
OR recurrence OR relapse OR progression) AND ("bladder
cancer"). Studies were considered eligible if: (i) they reported the
effect measure (as HRs, survival curves or log-rank p-values) of
COX2 protein expression on recurrence, progression or disease-
specific survival; (ii) COX2 was assessed in primary tumors
COX2 Expression and Bladder Cancer Prognosis
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exhibiting homogeneity in tumor histology ($75% UCB), and
subphenotype ($75% NMIBC or MIBC); (iii) they were written in
English or Spanish (Table S1). Reviews, abstracts, non-clinical
studies, and duplicate publications were excluded. HRs and
95%CIs were directly extracted from the publications whenever
available. For those reporting only the log-rank p-value or the
Kaplan–Meier survival curves, the HRs and 95%CIs were
independently calculated by two of the co-authors (MJC, AFSA)
using the spreadsheet prepared by Sydes and Tierney with any
discrepancies resolved by discussion [38]. In a few indicated cases,
authors were directly contacted for clarification or provision of
data not shown in the published manuscripts (Table S1). The level
of heterogeneity among studies was calculated by means of the I2
statistic [39], and publication bias was assessed by analyzing funnel
plots and Egger’s asymmetry test [40].
Statistical Analysis
Associations between demographic and clinico-pathological
parameters and COX2 expression were assessed using Fisher’s
exact test. In NMIBCs, expression was also assessed distinctly in
low-grade/risk (pTaG1/G2) and high-grade/risk (pTa/pT2G3)
tumors, based on our previous evidence suggesting differential
prognostic, genetic and molecular profiles between these sub-
groups [41,42]. Recurrence-free, progression-free, and overall
disease-specific survival curves were generated using the Kaplan-
Meier method, with statistical significance assessed using the log-
rank test. Time to each endpoint was calculated from date of
primary treatment to the date of event, date of last follow-up, or
date of patient’s death. Individuals who did not present any event
until the end of the study, those lost to follow-up, or those who
died from other causes were censored either at the time of last
medical visit or at death. Time to recurrence and progression were
defined by applying the ‘‘mid-time’’ between the date of the
previous disease-free visit and that when a new event was
diagnosed. Survival time was measured as the time from initial
treatment to death resulting from cancer. Univariable and
multivariable Cox-proportional hazards analysis was used to
calculate hazard ratios (HR) and 95% confidence intervals (CI).
Schoenfeld residual analysis did not suggest any departure from
the proportional hazards assumption in multivariable models.
All statistical analyses were done using STATA (version 10.1
SE, StataCorp, College Station, TX, USA). Statistical tests were
two-sided and p-values less than 0.05 were considered significant.
The REMARK [43] guidelines for prognostic studies as well as the
PRISMA [44] guidelines for systematic reviews and meta-analyses
were adhered to in the preparation of the manuscript.
Results
Patients and COX2 Expression in Bladder Cancer TMAs
COX2 expression was assessed in 557 patients with NMIBCs
and 216 individuals with MIBCs. Median COX2 expression was
0.121 au (range 0–42.590; interquartile range 1.382) in NMIBCs,
and 0.760 au (0–30.806; 3.600) in MIBCs (p-value = 4610212).
Representative COX2 immunostaining patterns in UCBs are
shown in Figure S1. Of patients with NMIBCs, 41% (230/557)
were treated only by transurethral resection, with the remainder
(56%) receiving endovesical BCG immunotherapy and/or che-
motherapy following transurethral resection, or other treatment
(3%; Table 1). Nearly half (46%) of patients with MIBCs were
treated by cystectomy, with the remainder receiving systemic
chemotherapy, radiotherapy, superficial or other treatment, or
some combination thereof (Table 2).
Table 1. Distribution of characteristics of patients with
NMIBCs by COX2 expression.
COX2 expression*
Patient characteristics Total, N
negative,
n
positive,
n P value{
557 346 211
Area 0,506
Barcelona 98 68 30
Valles 105 66 39
Elche 51 32 19
Tenerife 122 71 51
Asturias 181 109 72
Age (yrs.) 0,385
#60 140 81 59
.60 and #70 210 130 80
.70 207 135 72
Gender 0,891
Men 494 306 188
Women 63 40 23
Tumor Invasion ,0,0001
Ta 477 277 200
T1 80 69 11
Grade ,0,0001
GI 200 131 69
GII 219 95 124
GIII 138 120 18
Low/High Grade ,0,0001
Low (TaG1/TaG2) 408 221 187
High (TaG3/T1G2/T1G3) 149 125 24
Number of tumors 0,106
1 348 209 139
.1 178 120 58
missing 31 17 14
Tumour Size 0,564
#3 cm 294 188 106
.3 cm 111 67 44
missing 152 91 61
Number of Recurrences 0,409
none 366 232 134
at least 1 191 114 77
Treatment{ 0,393
TUR 230 133 97
TUR+BCG 158 105 53
TUR+Chem. 132 83 49
TUR+BCG+Chem. 19 14 5
Other 18 11 7
*COX2 expression score dichotomised at the threshold of positivitiy (0,340 au).
{Fisher’s exact test comparing distribution of COX-2 negative versus positive
patients; missing values excluded from analysis where applicable.
{TUR: transurethral resection; BCG: Bacillus Calmette-Guerin instillation; Chem.:
chemotherapy via endovesical instillation.
doi:10.1371/journal.pone.0045025.t001
COX2 Expression and Bladder Cancer Prognosis
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e45025
Table 2. Distribution of characteristics of patients with MIBCs by COX2 expression.
COX2 expression*
Patient Characteristics Total, N negative, N positive, N P value{
216 79 137
Area 0,207
Barcelona 39 16 23
Valles 36 9 27
Elche 15 9 6
Tenerife 39 14 25
Asturias 87 31 56
Gender 0,816
Men 194 72 122
Women 22 7 15
Age (yrs.) 0,426
#60 45 14 31
.60 and #70 84 35 49
.70 87 30 57
Tumor invasion 0,896
T2 114 42 72
T3 55 21 34
T4 47 16 31
Grade 0,326
GII 19 9 10
GIII 197 70 127
Metastases 0,296
M0 168 57 111
M1 29 13 16
Mx 19 9 10
Lymphatic invasion 0,862
N0 141 50 91
N1, N3 49 16 33
Nx 26 13 13
Number of tumors 0,008
1 146 63 83
.1 54 12 42
missing 16 4 12
Tumour size 0,572
#3 cm 53 19 34
.3 cm 66 28 38
missing 97 32 65
Treatment{ 0,417
Cystectomy 67 19 48
Cystectomy+Chem. 32 15 17
Chem. only 23 9 14
RT +/2 Chem. 19 7 12
Superficial Treatment 13 3 10
Others 61 25 36
missing 1 1 0
*COX2 expression score dichotomised at the threshold of positivity (0,340 au).
{Fisher’s exact test comparing distribution of patients with negative or positive COX-2 expression; missing, Nx and Mx values excluded from analysis where applicable.
{Chem.: Systemic chemotherapy; RT: Radiation therapy.
doi:10.1371/journal.pone.0045025.t002
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COX2 Expression and Clinicopathological Features
Two-hundred eleven (38%) NMIBCs and 137 (58%) MIBCs
expressed COX2 (Tables 1 and 2, respectively), with positive
expression defined as a score equal to or greater than the ROC-
derived threshold of 0.340 au. Patient and tumor characteristics in
the analyzed sample did not differ significantly from the initial
SBC/EPICURO study population with the exception of geo-
graphic region and tumor size in NMIBC patients (data not
shown). The distribution of COX2 positivity was assessed
according to established bladder cancer prognosticators including
tumor invasion and grade, tumor multiplicity, tumor size and
treatment, among others. Demographic factors like age, gender
and region were not associated with COX2 expression, nor was
the type of primary treatment received by patients (Tables 1 and
2). In NMIBCs, COX2 expression was significantly associated
only with T and G; being more prominent in low-grade/risk
pTaG1/2 tumors than in high-grade/risk pTa/pT1G3 tumors (p-
value,0.0001; Table 1). Further assessment of COX2 distribution
in relevant molecular subtypes of UCB [4], revealed a greater
proportion of pTaG2 than pTaG1 tumors positively expressing
COX2 in low-grade NMIBCs (p,0.0001, subtype 1; Figure S2).
COX2 expression did not differ among high-grade/risk NMIBCs
(p = 0.075), but a greater proportion of MIBCs positively expressed
COX2 than did all high-grade/risk NMIBCs combined
(p,0.0001, subtype 2; Figure S2). Only tumor multiplicity was
associated with positive COX2 expression in MIBC patients (p-
value = 0.008; Table 2).
COX2 Expression and Prognosis in Bladder Cancer
Patients
We analyzed the association of COX2 expression with tumor
recurrence and progression in patients with NMIBCs and with
progression and disease-specific survival in patients with MIBCs
(Table 3; Figure 1). When considered as a continuous variable in
the univariable analysis, COX2 expression was marginally
associated with an increased risk of recurrence in NMIBCs
(HR = 1.02, 95%CI = 1.00–1.04, p-value = 0.048; Table 3). How-
ever, this association disappeared upon multivariable analysis
when adjusting for region, gender, tumor stage and grade,
multiplicity, tumor size, and treatment. Moreover, COX2
expression was not significantly associated with recurrence in
NMIBCs when considered as a categorical variable, neither in the
univariable nor multivariable analyses (Figure 1A; Figure S3AC;
Table 3). Lastly, no significant association between COX2
expression and progression or survival was observed in patients
with NMIBCs or MIBCs, regardless of whether expression was
considered as a continuous or categorical variable in non-adjusted
or adjusted analyses (Figure 1B–D; Figure S3B, 3D–H; Table 3).
Meta-analysis of COX2 Expression and Bladder Cancer
Prognosis
Twenty publications on COX2 expression and bladder cancer
prognosis were identified through the literature review (Table S1)
[12–31]. Three of them lacked prognostic data, two overlapped
with other larger studies and four included patient cohorts that did
not meet the eligibility criteria outlined earlier, leaving 11
evaluable publications [12–14,19,21–25,28,29] plus the current
study for the meta-analysis (Figure S4). Studies were classified by
the tumor subtype(s) they reported on (i.e. NMIBC or MIBC), and
whether adjustment for covariates was considered for each
prognostic endpoint examined (i.e. univariable or multivariable;
Figures 2 and 3). Of the four meta-analyses conducted with
univariable data, only the metaHR of the association between
COX2 expression and recurrence in NMIBCs showed marginal
significance (metaHR = 1.35, 95%CI = 1.00–1.83; Figure 2). This
result was not affected by study heterogeneity (I2 p-value = 0.13)
but exhibited significant publication bias, as evidenced by Egger’s
test (p-value = 0.019). The remaining meta-analyses considering
univariable data suggested increased, albeit non-significant, risks of
tumor progression in patients with NMIBCs (metaHR = 2.07,
95%CI = 0.76–5.64) and MIBCs (metaHR = 1.45, 95%CI = 0.77–
2.74), and death in patients with MIBCs (metaHR = 1.13,
95%CI = 0.8–1.59; Figure 2). Notably, the summary effect for
progression in NMIBCs and that observed for survival in MIBCs
were both significantly affected by study heterogeneity (I2 p-values:
0.006 and 0.004, respectively), with the former also significantly
influenced by publication bias (Egger’s test p-value = 0.001).
Due to a paucity of published prognostic studies performing
multivariable analysis on patients with NMIBCs, we could only
address the multivariable meta-association with progression and
survival in patients with MIBCs (Figure 3). A small, non-significant
increased summary risk of progression (metaHR = 1.12,
95%CI = 0.53–2.35; Figure 3) was observed in COX2 expressing
MIBCs that was unaffected by study heterogeneity (I2 p-
value = 0.139). Similarly, a null summary effect was observed for
survival (metaHR = 0.97, 95%CI = 0.69–1.36; Figure 3). This
effect was influenced neither by study heterogeneity (I2 p-
value = 0.114) nor by publication bias (Egger’s test p-val-
ue = 0.108.
Discussion
Despite many published studies, contradictory findings prevail
on COX2 expression as an independent prognostic marker in
patients with UCB. The current study suggests that COX2
expression is not an independent marker associated with
recurrence, progression or survival in patients with UCB.
Using the largest cohort of patients with NMIBCs evaluated for
COX2 expression to date, we observed that 38% of these tumors
expressed the protein. Other groups have reported frequencies
ranging from 53–88%; however, these studies used different
COX2 antibodies and expression evaluation techniques and had
smaller sample sizes [16,28,29,45,46]. In accordance with
reported results [11,18,45] we observed significantly higher
COX2 expression in MIBCs (58%) than in NMIBCs. This
frequency is similar to that observed in other large, histologically
homogeneous studies [21,28], while groups using heterogeneous
cohorts of squamous and transitional cell carcinomas report
frequencies different from our own [12,29]. Collectively, these
findings reiterate the importance of homogeneity, or stratification,
in tumor marker studies.
The association between COX2 and clinico-pathological
characteristics remains a contentious issue in the literature. The
majority of studies report an association between COX2
overexpression and advanced tumor invasion and grade, but use
heterogeneous populations of NMIBCs and MIBCs in their
assessments [21,25,26,28,47]. Given the known disparity in
COX2 expression between NMIBCs and MIBCs, an association
of this type would be expected in a mixed tumor population. After
pooling NMIBCs and MIBCs in our study we also observe a
strong significant association between COX2 overexpression and
advanced tumor invasion (p.0.0001) and grade (p.0.0001).
Notably, several groups report no association between COX2
expression and T and G [14,29,45]; especially those working
strictly with homogeneous cohorts of MIBCs [12,23]. Similarly, in
our study, COX2 expression did not differ significantly among
pT2, pT3 and pT4 tumors (p = 0.896). Interestingly, we observed
COX2 Expression and Bladder Cancer Prognosis
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lower COX2 positivity in pT1 and high-grade/risk NMIBCs, than
in pTa and low-grade/risk NMIBCs tumors. This result may seem
counterintuitive if grade progression is considered a linear trait
and COX2 expression is deemed to increase linearly with T and
G. However, there is strong evidence indicating that UCB exists as
two molecularly distinct subtypes, with high-grade/risk NMIBCs
having a molecular signature more similar to MIBCs than to low-
grade/risk NMIBCs [4,42]. In this respect, we observed that
COX2 positivity increased significantly with increasing T and G
within each molecular tumor subtype (Figure S2). Shirahama et al.
[26] reported a COX2 distribution similar to ours, observing 8%
positivity in pT1 tumors and 50% in MIBCs when using whole
section staining and a 5% expression threshold. Collectively, these
results reiterate the disparity in COX2 expression between
NMIBCs and MIBCs first reported by Komhoff et al. [47], and
highlight the importance of considering expression within the
proper molecular context.
To minimize the effects resulting from selecting an arbitrary
expression threshold, we investigated COX2 protein expression
as a continuous variable and three categorical variables. Only
when considered as a continuous variable in the univariable
analysis was COX2 expression found to be associated with a
slight increase in the risk of recurrence. The meta-analysis,
consisting of five other univariable studies, reiterated this
association and showed a 35% increased risk of recurrence in
patients with COX2 expressing NMIBCs. However, both effect
estimates exhibit only marginal significance, suggesting that the
observed associations may be due to chance. Moreover, the
association observed in the univariable analysis did not hold after
adjustment for conventional prognostic factors of recurrence in
the multivariable analysis. Lastly, the summary effect observed in
the meta-analysis may have been skewed by two small studies
which selected only high risk NMIBCs (T1G3 [19] and Cis [24]).
When a sensitivity analysis was performed removing these two
studies from the meta-analysis, the association between recur-
rence and COX2 expression was no longer maintained
(metaHR = 1.14, 95%CI = 0.94–1.38). The observed disparity
between effect estimates of progression in the present study and
the meta-analysis could also be attributed to the inclusion of
these two studies. Upon their exclusion, the summary HR
showed no association with progression (metaHR = 0.98,
95%CI = 0.47–2.03). These results do not support a role for
COX2 expression in NMIBCs as an independent prognostic
marker of recurrence or progression.
Several groups have investigated the ability of COX2 expression
to predict outcome in patients with MIBCs. Despite wide inter-
Table 3. Analysis of COX2 expression in NMIBCs and MIBCs; univariable and multivariable analyses.
Univariate COX-regression Multivariate COX-regression{
Score Categorization* Patients, n Events, n HR (95% CI) P value{ Patients, n Failures, n HR (95% CI) P value{
Non-muscle invasive tumors
Recurrence 1
Continuous 556 191 1,02 1,00–1,04 0,048 401 141 1,02 1,00–1,04 0,140
Negative vs. Positive 556 191 1,08 0,81–1,44 0,612 401 141 1,11 0,78–1,59 0,555
Median 556 191 1,08 0,82–1,44 0,583 401 141 1,17 0,82–1,67 0,390
Extreme tertiles 370 127 1,06 0,89–1,27 0,483 268 94 1,08 0,86–1,37 0,510
Progression
Continuous 557 48 0,92 0,84–1,01 0,094 526 43 0,96 0,87–1,05 0,350
Negative vs. Positive 557 48 0,72 0,39–1,33 0,302 526 43 1,38 0,61–3,11 0,434
Median 557 48 0,67 0,38–1,20 0,181 526 43 1,11 0,53–2,33 0,780
Extreme tertiles 371 33 0,71 0,49–1,01 0,059 351 29 0,92 0,54–1,56 0,750
Muscle invasive tumors
Progression
Continuous 216 131 0,99 0,96–1,03 0,617 189 110 0,99 0,96–1,03 0,750
Negative vs. Positive 216 131 0,94 0,66–1,34 0,734 189 110 0,85 0,56–1,29 0,448
Median 216 131 0,97 0,69–1,37 0,869 189 110 0,89 0,60–1,32 0,560
Extreme tertiles 144 85 0,92 0,75–1,14 0,464 128 75 0,90 0,70–1,15 0,410
Disease specific survival
Continuous 216 110 1,00 0,97–1,04 0,908 187 89 1,01 0,97–1,05 0,730
Negative vs. Positive 216 110 0,91 0,61–1,34 0,627 187 89 0,77 0,48–1,23 0,267
Median 216 110 0,94 0,64–1,36 0,726 187 89 0,78 0,50–1,23 0,290
Extreme tertiles 144 68 0,90 0,71–1,15 0,407 126 57 0,78 0,58–1,04 0,090
*Expression cut-points used for categorical variables: "Neg. vs. Pos." - NMIBC/MIBC: 0.340; "Median" - NMIBC: 0.121, MIBC: 0.760; "Extreme tertiles" - NMIBC: (,0.0239,
.0.586), MIBC: (,0.270, .2.149).
{Multivariate models adjusted for established bladder cancer prognostic factors as follows: NMIBC Recurrence adjusted by region, gender, tumour stage and grade, #
tumours, size of tumours, and treatment; NMIBC Progression adjusted by region, # recurrences, age, tumour stage and grade, # tumours, and treatment; MIBC
Progression adjusted by region, tumour stage, treatment, and presence of nodes; MIBC Survival adjusted by region, tumour stage, treatment, presence of nodes, and
metastases.
{Cox proportional hazards analysis.
1One patient excluded due to incomplete follow-up record.
doi:10.1371/journal.pone.0045025.t003
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study variation in methodology, antibodies used, sample size, and
adjustment parameters in the case of multivariable analyses, the
majority of these studies did not identify any significant association
between COX2 expression and progression or survival, consistent
with our findings [13,14,23,28,29]. Shariat and Margulis and their
colleagues observed a negative association between high COX2
expression and tumor progression and mortality [21,25]. Howev-
er, both studies relied on heterogeneous sample populations which
included a small proportion of patients with NMIBCs; potentially
accounting for the observed associations given the disparity in
COX2 expression between superficial and advanced bladder
tumors [45]. In another study, Wulfing et al. reported that high
COX2 expression was an independent predictor of poor overall
survival in a subgroup of 62 patients with MIBC treated with
cisplatin-based chemotherapy [29]. We did not identify any
meaningful interaction between COX2 expression and treatment
(data not shown), and were unable to replicate their findings in a
smaller subset of 39 patients treated with cisplatin (HR = 1.47,
95%CI = 0.48–4.51, p-value = 0.497). Aziz et al. reported a 36%
survival advantage associated with increased COX2 levels in a
cohort of 266 patients with MIBCs (221 with UCB) that was
independent of lymph node status and neo/adjuvant chemother-
apy [12]. While we also observed improved survival among
patients with COX2 overexpressing MIBCs, this association did
not reach significance, consistent with other univariable [23,28]
and multivariable [26] analyses.
Our study had a large sample size, included only incident cases
and relied on extensive and accurately acquired follow-up
information spanning ten years. Additionally, we used automated
scoring of immunostained TMAs, a strategy providing a repro-
ducible assessment of expression that correlated highly with the
independent evaluation of a subset of samples by an independent
pathologist. COX2 staining was done in one laboratory to avoid
heterogeneity in immunohistochemical staining and scoring, and
evaluated as a continuous variable in the prognostic analyses to
avoid potential bias related to selection of an expression threshold.
Moreover, the sample population provides an accurate represen-
tation of bladder cancer in the general population as no inclusion
criteria were applied in the recruitment process which included a
good mix of referral centers and county hospitals. Lastly, the
recommendations of the REMARK and PRISMA studies were
followed in all of the reported analyses.
Despite these considerations and attempts to accurately quantify
COX2 expression only in epithelial cells, the pathologist-trained
automated imaging system may have incorporated some immu-
nostained stromal material found on the tissue core, thereby
increasing type I error. To reduce potential error we averaged the
expression scores from duplicate cores and also explored a method
investigated by Henriksen et al. [48] in which the higher score was
used (data not shown). Both methods produced similar material
associations between COX2 expression and clinico-pathological
parameters or HRs. Moreover, adjusted analyses for progression
Figure 1. Kaplan-Meier survival curves corresponding to failures in superficial (A, B) and invasive (C, D) tumors for specified
prognostic endpoints. Dashed curves: patients with tumors positive for COX2 protein staining; solid curves: patients with tumors negative for
COX2 protein staining. Significance values from two-sided logrank test.
doi:10.1371/journal.pone.0045025.g001
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in NMIBCs should be interpreted cautiously given the low number
of events in relation to covariates. Also, different patient
management practices across recruitment hospitals could increase
sample heterogeneity, necessitating the inclusion of both recruit-
ment area and treatment regimen in our multivariable analyses.
The results presented herein focus on COX2 expression levels
measured in tumor epithelial cells – only one aspect of the complex
interplay between the tumor and the host immune/inflammatory
response [49]. The prognostic potential of COX2 (if any) may only
be revealed when considered together with other tumoral markers.
When investigating several potential prognostic parameters in
UCB, Hilmy et al. concluded that systemic factors of the
inflammatory response such as levels of C-reactive protein were
superior to tumor-based factors such as grade, COX2 expression
or T-lymphocytic infiltration [18]. Moreover, in models of cervical
cancer, Ferrandina et al. observed that while COX2 expression
was mutually exclusive in the tumor and stromal inflammatory
cells, high expression in both cell types could be used as an
independent marker of poor survival [50]. Future studies
investigating the prognostic value of COX2 expression in UCB
should take into consideration the multi-factorial and multi-
dimensional context of the inflammatory response during carci-
nogenesis.
The current study is the largest to investigate COX2 expression
as an independent marker of outcome in a prospective cohort of
UCB patients. These findings, supported by a meta-analysis that
included our own data and that from other relevant studies, do not
Figure 2. Forest plots from selected univariable studies indicating the risk of reaching the indicated prognostic endpoints in non-
muscle invasive (NMIBC; two upper panels), and muscle invasive (MIBC; two lower panels) UCBs in the presence of urothelial COX2
expression.
doi:10.1371/journal.pone.0045025.g002
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support COX2 tumor cell expression being an independent
prognosticator of UCB.
Supporting Information
Figure S1 Immunohistochemical staining of COX2 in
primary UCBs on TMAs. Expression was scored as a product
of the percentage of epithelial area stained and the staining
intensity using automated imaging analysis. A score of ,0.340 au
was considered negative for COX2 expression, while a score of
$0.340 was considered positive. Representative sections of a
pTaG1 UCB lacking COX2 expression (A and D) and a pT2G3
UCB expressing COX2 (B and E) are shown. Normal colon tissue
was used as a positive control (C and F). Upper panels show
sections under 100x magnification (A-C); lower panels show
sections under 200x magnification (D–F).
(PDF)
Figure S2 Distribution of positive COX2 expression in
urothelial carcionomas of the bladder classified by their
molecular and pathological stage-grade subtypes. Posi-
tive COX2 expression assessed as described in Figure S1.
Statistical significance assessed using Fisher’s exact test with a
0.05 significance level. pT1G2 tumors excluded due to low sample
size in the current study (n = 11), and a reported tendency to
overlap both molecular subtypes.
(PDF)
Figure S3 Kaplan-Meier survival curves corresponding
to failures in superficial (A, B, C, D) and invasive (E, F,
G, H) tumors for specified prognostic endpoints and
quantiles of COX2 expression. Dashed curves: patients with
tumors expressing COX2 at lower specified quantiles; solid curves:
patients with tumors expressing COX2 at upper specified
quantiles. Significance values from two-sided logrank test.
(PDF)
Figure S4 Flow diagram of study selection and inclusion
in meta-analysis.
(PDF)
Figure 3. Forest plots from selected multivariable studies indicating the risk of reaching the indicated prognostic endpoints in non-
muscle invasive (NMIBC; two upper panels), and muscle invasive (MIBC; two lower panels) UCBs in the presence of urothelial COX2
expression.
doi:10.1371/journal.pone.0045025.g003
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Supporting Table 1.  Main characteristics of eligible studies used in meta-analysis
First Authour Year Country
Patients w/ 
follow-up
Median 
follow-up 
(months) Histology Stage Tissue
Antibody for IHC, 
dilution
Definition of COX2 
positivity HR Estimation Evaluable Ref.
Aziz 2010 Canada 266 NS TCC (>75%), SCC T2-T4 whole section Cayman, 200 > 5% HRs/95% CIs Yes 12
Bamias 2008 Greece 42 72 TCC pT3, pT4 whole section SantaCruz, 50 > 10% HRs/95% CIs; from author Yes 13
Diamantopoulou 2005 Greece 55 48 TCC pTa, pT1; pT2-T4 whole section SantaCruz, 130 >= 10% HRs/95% CIs; from author Yes 14
Eltze 2005 Germany 132 88 TCC pT1; pT2-pT4 whole section Cayman, 200 > 0, categorical Surv. curves No 15
Friedrich 2003 Germany 91 26 TCC pTa, pT1 NS Oxford, 200 > 10% No data No 16
Gudjonsson 2011 Sweden 52 37,2 TCC Ta TMA Dako, 5 1, categorical HRs/95% CIs No 17
Hilmy 2006 UK 103 60 TCC Tis, pTa, pT1; pT2-pT4 whole section Cayman, NS tertiles examined HRs/95% CIs No 18
Kim 2002 South Korea 37 27 TCC T1G3 whole section SantaCruz, 200 > 5% Surv. curves Yes 19
Liedberg 2008 Sweden 128 16 TCC Tis, pT0, pT1; pT2-pT4 TMA Dako, 5 > 0, categorical No data No 20
Margulis 2007 USA 157 66 TCC Ta, Tis; T1-T4 (>75%) TMA SantaCruz, NS > 10% Surv. curves; HRs/95% CIs Yes 21
Mokos 2006 Croatia 70 24 TCC Tis, Ta, T1 whole section Oxford, 50 > 0%, categorical Surv. curves Yes 22
Naruse 2010 Japan 46 NS TCC pT2-pT4 whole section SantaCruz, 20 > 10% Surv. curves Yes 23
Shariat 2003a USA 37 120 TCC Tis, pT1 whole section NS, 100 > 10% rec.; > 20% prog. Surv. curves Yes 24
Shariat 2003b USA 80 101 TCC Tis, pTa, pT1; pT2-pT4 (>75%) whole section SantaCruz, 100 >10% of cells Surv. curves Yes 25
Shirahama 2001 Japan 108 75 TCC pT1; pT2-T4 whole section NS, 200 >= 5% HRs/95% CIs No 26
Tiguert 2002 Canada 172 NS TCC MIT NS NS, 100 >= 5% of cells Surv. curves No 27
Wild 2005 Germany 617 39 TCC pTa, pT1; pT2-4 TMA Cayman, 5ug/ml > 0, categorical HRs/95% CIs; from author Yes 28
Wulfing 2004 Germany 157 88 TCC (>75%), SCC Tis, pT1; pT2-pT4 (>75%) whole section Cayman, 200 > 0, categorical Surv. curves; HRs/95% CIs Yes 29
Yoshimura 2001 Japan 118 NS TCC, SCC pTis, pT0, pT1; pT2-pT4 whole section "in house", 100 > 0, categorical No data No 30
Youssef 2010 Egypt 315 63,2 TCC (<75%), SCC, AD pT1; pT2-pT4 TMA ThermoFisher, 200 > 20% Surv. curves; HRs/95% CIs No 31
Abbreviations: AD, adenocarcinoma; HRs/95% CIs, hazard ratios/95% confidence intervals; MIT, muscle invasive tumour; NMIT, non-muscle invasive tumour; NS, not specified; Ref., publication reference; Surv. Curves, survival curves; SCC, squamous
cell carcinoma; TCC, transitional cell carcinoma; TMA, tissue microarray.
negative vs. positive staining
Notes/reason excluded
only bladder tumours analyzed
overlap with Wulfing et al 2004
insufficient prognostic data
38% primary tumours in cohort
pooled cohort of N/MITs
no prognostic data
negative vs. positive staining
no prognostic data
TCC (<75%)
pooled cohort of N/MITs
overlap with Aziz et al 2010
